Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Morris, E
Thomson, K
Craddock, C
Milligan, D
Smith, GM
Parker, A
Schey, S
Winfield, D
Chopra, R
Littlewood, T
Tighe, J
Hunter, A
Kyriakou, C
Kottaridis, P
Peggs, K
Linch, D
Goldstone, A
Mackinnon, S
机构：
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
139
引用
收藏
页码：40A / 40A
页数：1
相关论文
共 50 条
  • [1] Long-term follow-up of an alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant (RIT) regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL)
    Morris, E
    Thomson, K
    Craddock, C
    Milligan, D
    Smith, G
    Parker, A
    Schey, S
    Winfield, D
    Chopra, R
    Littlewood, T
    Tighe, J
    Hunter, A
    Kyriakou, C
    Kottaridis, P
    Linch, D
    Goldstone, A
    Peggs, K
    Mackinnon, S
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 : 29 - 29
  • [2] Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL)
    Morris, E
    Mackinnon, S
    TRANSFUSION AND APHERESIS SCIENCE, 2005, 32 (01) : 73 - 83
  • [3] Reduced intensity allogeneic transplantation for non-Hodgkin's Lymphoma: Extended follow-up of an alemtuzumab-containing regimen.
    Thomson, KJ
    Morris, EC
    Milligan, D
    Cook, G
    Cavet, J
    Craddock, C
    Hunter, A
    Schey, S
    Parker, A
    Goldstone, AH
    Linch, DC
    Peggs, KS
    Mackinnon, S
    BLOOD, 2005, 106 (11) : 120A - 121A
  • [4] Alemtuzumab (CAMPATH-1H) for the Treatment of Acute Rejection in Kidney Transplant Recipients: Long-Term Follow-Up
    Clatworthy, Menna R.
    Friend, Peter J.
    Calne, Roy Y.
    Rebello, Perpetua R. U.
    Hale, Geoffrey
    Waldmann, Herman
    Watson, Christopher J. E.
    TRANSPLANTATION, 2009, 87 (07) : 1092 - 1095
  • [5] Long-term follow-up of reduced intensity transplantation with an alemtuzumab-containing regimen for aggressive non-Hodgkins lymphoma
    Thomson, Kirsty
    Morris, Emma
    Bloor, Adrian
    Cook, Gordon
    Milligan, Donald
    Parker, Anne
    Craddock, Charles
    Yung, Lynny
    Chakraverty, Ronjon
    Peggs, Karl
    Mackinnon, Stephen
    BLOOD, 2007, 110 (11) : 495A - 496A
  • [6] Long term follow-up of CEOP in the treatment of HIV related non-Hodgkin's lymphoma (NHL)
    Davis, AJ
    Goldstein, D
    Milliken, S
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1998, 28 (01): : 28 - 32
  • [7] Autotransplantation for relapsed or refractory non-Hodgkin’s lymphoma (NHL): long-term follow-up and analysis of prognostic factors
    AP Rapoport
    R Lifton
    LS Constine
    RE Duerst
    CN Abboud
    JL Liesveld
    CH Packman
    S Eberly
    RF Raubertas
    BA Martin
    WR Flesher
    PA Kouides
    JF DiPersio
    JM Rowe
    Bone Marrow Transplantation, 1997, 19 : 883 - 890
  • [8] Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors
    Rapoport, AP
    Lifton, R
    Constine, LS
    Duerst, RE
    Abboud, CN
    Liesveld, JL
    Packman, CH
    Eberly, S
    Raubertas, RF
    Martin, BA
    Flesher, WR
    Kouides, PA
    DiPersio, JF
    Rowe, JM
    BONE MARROW TRANSPLANTATION, 1997, 19 (09) : 883 - 890
  • [9] Optimum conditions for radioimmunotherapy of non-Hodgkin's lymphoma (NHL) using CAMPATH-1H monoclonal antibody (Mab)
    Hadjiyiannakis, P
    Hale, G
    Clutterbuck, R
    Eccles, S
    Carnochan, P
    Lebozer, C
    McCready, VR
    Catovsky, D
    Horwich, A
    Dyer, MJS
    BRITISH JOURNAL OF CANCER, 2000, 83 : 16 - 16
  • [10] Primary non-Hodgkin's malignant lymphoma of the breast: long-term follow-up
    Imai, T
    Shiga, T
    BREAST, 2004, 13 (02): : 152 - 154
12345